Alpha-1-antitrypsin inhalation - Grifols

Drug Profile

Alpha-1-antitrypsin inhalation - Grifols

Alternative Names: Alpha-1 HC; Alpha-1 HC aerosol; VR 179

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Bayer
  • Developer Grifols; Vectura
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency; Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Jul 2015 Phase-II development is ongoing in Cystic fibrosis in USA (inhalation)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top